Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6401MR)

This product GTTS-WQ6401MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6401MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14909MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ5753MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ10434MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ14165MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ8200MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ15985MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ834MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ14414MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO 24-7375
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW